Aptorum Group Ltd

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) announced it has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a deficiency letter on March 5, 2026, for its common stock trading below $1.00 per share for 30 consecutive business days. Nasdaq confirmed on August 4, 2026, that the company's stock closed at or above $1.00 for 10 consecutive business days, thereby resolving the compliance issue.

Aptorum Group Ltd completed its merger with DiamiR Biosciences Corp. on July 20, 2026, following shareholder approval. Concurrently, Aptorum redomiciled to Delaware, changed its name to Niki BioSolutions, Inc., and will trade on Nasdaq under the new ticker "NIKI" with a new CUSIP. The company also effected a 1-for-10 reverse stock split to maintain Nasdaq listing compliance and adopted a new 2026 Incentive Plan.

Aptorum Group announced that its merger with DiamiR Biosciences Corp. is anticipated to close around July 20, 2026. In connection with the merger, Aptorum will effect a 1-for-10 reverse share split and redomicile as a Delaware company under the new name Niki BioSolutions, Inc. The post-merger company will trade on Nasdaq under the new ticker "NIKI" on a split-adjusted basis, with the reverse split intended to maintain Nasdaq listing compliance.

Aptorum Group Limited announced an amendment to its Agreement and Plan of Merger with DiamiR Biosciences Corp., extending the termination date from December 31, 2025, to July 31, 2026. This extension also applies to the related Management Services Agreement and Intellectual Property Licensing Agreement. The parties continue to work towards satisfying the closing conditions for the merger, which will result in DiamiR becoming a wholly-owned subsidiary of Aptorum.

Aptorum Group Limited announced that shareholders of both Aptorum Group and DiamiR Biosciences Corp. have approved their all-stock merger transaction. The merger is anticipated to close before fiscal year 2027, after which the combined entity will operate as Niki BioSolutions, Inc. Additionally, DiamiR Biosciences has entered into a collaboration with AlzLabs Precision Diagnostics to generate blood-based biomarker data for Alzheimer's disease, focusing on protein and microRNA markers.

Aptorum Group Ltd. announced that its shareholders, along with DiamiR Biosciences Corp.'s shareholders, approved the proposed all-stock merger transaction. This approval is a significant step towards DiamiR becoming a wholly-owned subsidiary of Aptorum Group. At the Extraordinary General Meeting, Aptorum shareholders also approved a share consolidation, domestication to Delaware, issuance of new stock for the merger, a new stock incentive plan, and the appointment of five directors for the post-merger company. The merger is expected to close before fiscal 2027, subject to remaining closing conditions.